TLE3 as a marker for chemotherapy
View Patent ↗Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
1. A method for selecting a chemotherapy for a breast cancer patient comprising steps of:
providing a cancer sample from a breast cancer patient;
detecting the presence of expression of TLE3 in the cancer sample; and
selecting a taxane or taxane derivative for chemotherapy of the cancer patient when the TLE3 expression is present.
2. The method of claim 1 , wherein the step of detecting comprises steps of:
providing a negative control sample;
detecting a level of TLE3 expression in the negative control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the negative control sample.
3. The method of claim 1 , wherein the step of detecting comprises steps of:
providing a positive control sample;
detecting a level of TLE3 expression in the positive control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the positive control sample.
4. The method of claim 1 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
5. The method of claim 4 , wherein the interaction partner is an antibody.
6. The method of claim 1 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
7. The method of claim 6 , wherein the taxane is paclitaxel.
8. The method of claim 6 , wherein the taxane is docetaxel.
9. The method of claim 4 , wherein the step of selecting comprises selecting a taxane for chemotherapy.
10. The method of claim 9 , wherein the taxane is paclitaxel.
11. The method of claim 9 , wherein the taxane is docetaxel.
12. The method of claim 5 , wherein the step of selecting comprises selecting a taxane for chemotherapy.
13. The method of claim 12 , wherein the taxane is paclitaxel.
14. The method of claim 12 , wherein the taxane is docetaxel.
15. The method of claim 6 , wherein the step of selecting comprises selecting a taxane for chemotherapy.
16. The method of claim 15 , wherein the taxane is paclitaxel.
17. The method of claim 15 , wherein the taxane is docetaxel.